CERS is expected to report earnings to rise 67.00% to -1 cents per share on October 29
Q3'26
Est.
$-0.02
Q2'26
Beat
by $0.02
Q1'26
Beat
by $0.04
Q4'25
Est.
$-0.01
Q3'25
Beat
by $0.03
The last earnings report on July 30 showed earnings per share of 0 cents, beating the estimate of -2 cents. With 1.55M shares outstanding, the current market capitalization sits at 566.28M.
A.I. Advisor
published General Information
General Information
a developer of the INTERCEPT Blood System for platelets and plasma
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
CERS saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for CERS moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In of the 56 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
CERS moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CERS crossed bearishly below the 50-day moving average on August 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CERS entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CERS's RSI Oscillator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 14, 2026. You may want to consider a long position or call options on CERS as a result. In of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CERS just turned positive on August 13, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .
CERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.084) is normal, around the industry mean (11.035). P/E Ratio (0.000) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.006). CERS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (2.469) is also within normal values, averaging (34.463).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
